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Purpose: Poor adherence to tyrosine kinase inhibitors (TKIs) could compromise the control 
of chronic myeloid leukemia (CML) and contributes to poorer survival. Little is known about 
how medication-related issues affect CML patients’ adherence to TKI therapy in Malaysia. 
This qualitative study aimed to explore these issues.
Patients and methods: Individual face-to-face, semistructured interviews were con-
ducted at the hematology outpatient clinics of two medical centers in Malaysia from 
August 2015 to January 2016. CML patients aged 18 years who were prescribed a TKI were 
invited to participate in the study. Interviews were audio-recorded, transcribed verbatim, and 
thematically analyzed.
Results: Four themes were identified from 18 interviews: 1) concerns about adverse reactions 
to TKIs, 2) personal beliefs regarding the use of TKIs, 3) mismanagement of TKIs in daily lives, 
and 4) financial burden in accessing treatment. Participants skipped their TKIs due to ineffective 
emesis control measures and perceived wastage of medication from vomiting. Participants also 
modified their TKI therapy due to fear of potential harm from long-term use, and stopped taking 
their TKIs based on belief in curative claims of traditional medicines and misconception about 
therapeutic effects of TKIs. Difficulty in integrating the dosing requirements of TKIs into daily 
lives led to unintentional skipping of doses, as well as the risk of toxicities from inappropriate 
dosing intervals or food interactions. Furthermore, financial constraints also resulted in delayed 
initiation of TKIs, missed clinic appointments, and treatment interruptions.
Conclusion: Malaysian CML patients encountered a range of medication-related issues 
leading to a complex pattern of nonadherence to TKI therapy. Further studies should investigate 
whether regular contact with patients to improve understanding of treatment rationale, to elicit 
and address patients’ concerns about adverse reactions, and to empower patients with skills 
to self-manage their medications might promote better adherence to TKIs and improve CML 
patients’ outcome.
Keywords: medication-related issues, adherence, tyrosine kinase inhibitors, chronic myeloid 
leukemia, qualitative study, thematic analysis
Introduction
Chronic myeloid leukemia (CML) is a rare type of cancer that occurs in 0.7–1.8 per 
100,000 population annually.1 Owing to effective treatment with tyrosine kinase 
inhibitors (TKIs), CML has become a chronic disease with a rising prevalence 
globally, expected to plateau at 35 times its annual incidence by 2050.1 In Malaysia, 
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~740 new cases of leukemia are diagnosed annually,2 of 
which CML accounts for 15%. Since the first TKI, imatinib, 
was launched in Malaysia in 2003, the overall survival rate 
of CML patients has reached 94.3% at 10 years.3 It is esti-
mated that about 1,500 CML patients are seeking treatment in 
Malaysia. Although the possibility of stopping TKI therapy in 
CML patients who have achieved deep molecular responses 
is a topic of active debate and investigation,4,5 lifelong treat-
ment remains the current standard of care.6
Although the survival of CML patients has increased 
markedly, some patients are not able to achieve a satisfac-
tory response to a given TKI, while others respond to TKIs 
initially but the response is later lost.6 These suboptimal 
treatment responses have been attributed to genetic variation 
in cellular drug uptake, development of genetic mutations, 
and poor adherence to TKIs.6 It has been estimated that 
3%–56% of CML patients are not adherent to their prescribed 
TKI therapy.7 Several studies have indicated that poor adher-
ence to TKIs compromises disease control,8,9 contributes to 
a higher mortality,10 and also increases health care resource 
utilization and the economic burden.11
A retrospective study in the United States of America 
found that CML patients on long-term TKI therapy are 
prone to developing certain medication-related issues such 
as side effects, drug interactions, and poor accessibility due 
to out-of-pocket payments.12 Health care providers may not 
be fully aware of the challenges faced by CML patients in 
managing their TKI therapy. Discrepancies between the 
perspectives of health care providers and CML patients 
on adherence to TKIs13,14 and health-related quality of life 
have also been reported.15 To understand the medicine-
taking practices of CML patients, qualitative studies in the 
United Kingdom, Taiwan, and Australia have demonstrated 
some psychological factors that facilitate TKI adherence, 
including faith in clinicians,16 belief in treatment efficacy,17 
and comparison to other patients in worse circumstances.14 
These studies also found that side effects, forgetfulness, 
complacency, lack of access to medical advice, and poor 
communication with health care providers are important 
barriers to TKIs adherence.14,16 However, given the role of 
sociocultural context in adherence to long-term medication,18 
patient’s perspective influencing adherence to TKIs reported 
in these developed countries may not be entirely applicable 
to other countries.
Malaysia is a developing country with a multiethnic popu-
lation. The median age at diagnosis of CML (48 years)19 is 
lower than in other countries (57–60 years).1 It has previously 
been reported that approximately one third of CML patients 
in Malaysia have suboptimal adherence to imatinib.20 This 
was significantly correlated with the duration of imatinib 
supply and also appeared to be linked to the number of con-
comitant medicines.21 The current study seeks to understand 
the reasons for nonadherence to TKIs in Malaysian patients 
with CML by exploring medication-related issues using 
qualitative methodology.
Methods
study design and settings
A qualitative approach was adopted to enable participants 
to express their thoughts freely, allowing the researcher a 
better opportunity to examine patients’ medication-taking 
experience in depth.22 Individual face-to-face interviews were 
conducted at the hematology outpatient clinics of Ampang 
Hospital (AH) and University Malaya Medical Centre 
(UMMC) in Malaysia from August 2015 to January 2016.
UMMC is a tertiary teaching hospital partly financed by 
the Ministry of Education Malaysia. It is located in Kuala 
Lumpur, the main business and administrative region in 
Malaysia. AH is a public hospital located in a state adjacent 
to Kuala Lumpur; this national referral center for hematol-
ogy is fully funded by the Ministry of Health Malaysia. At 
the time of the study, ~200 and 70 CML outpatients were 
obtaining TKIs via the Malaysia Patients Assistance Program 
at the two medical centers, respectively. Ethical approvals 
were granted by the Medical Research and Ethics Committee 
Ministry of Health (NMRR-14-1466-23315) and Medical 
Ethics Committee of University Malaya Medical Centre 
(MECID-201411-802) before commencement of the study.
recruitment of participants
CML patients aged 18 years who were prescribed a TKI 
were invited to participate in the study when waiting at the 
clinic to see their doctors. Eligible patients were identified 
by screening the medical records. Patients who had cognitive 
or psychiatric disorders or who already had evidence of drug 
resistance were excluded. A purposive sampling strategy was 
used23 to include patients with a maximum variation of age 
groups, education levels, and treatment responses, and thus 
allowed a diverse range of medication-taking experiences.
Data collection
Semistructured interviews to explore participants’ experiences 
with TKI therapy were conducted in a room adjacent to the 
clinic before or after their appointments with the doctor. 
Before the interview, participants were provided with an 
information sheet about the study and informed of the study 
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procedure, including the expected length of the interview 
(30–60 minutes). All participants provided written informed 
consent, including permission to audio-record the interview. 
Demographic information was collected from participants 
during the interview, and treatment-related information was 
obtained from their medical records.
All interviews were conducted by a researcher (BKT) 
as guided by an interview schedule that contained open-
ended questions (Table 1) aimed at exploring the views and 
preferences, practices, medication-taking issues, and concerns 
of patients in relation to their ability to use TKIs effectively 
and safely. This interview schedule was designed on the basis 
of the relevant literature24 and consultation with experts (SBT 
and PCB). It was piloted on three participants and then used 
in the main interviews with no amendments. Results from 
the pilot study were included in the final analysis.
Data analysis
A thematic analysis was performed based on the six phases of 
Braun and Clarke,25 which included the following procedures: 
1) all interviews were transcribed verbatim by a researcher 
who conducted the interviews (BKT) and repeatedly read to 
gain familiarity with the content. Interviews in Malay and 
Mandarin were translated into English by a professional 
translator and verified by BKT. All transcripts were imported 
into qualitative data analysis software – NVivo (version 10, 
QSR International Pty Ltd. Victoria, Australia). 2) Initial 
coding was performed by BKT and reviewed against the 
transcripts by PCB and SSC. 3) To ensure reliability of the 
analyses, two researchers (BKT and SB) independently 
searched for potential themes across the codes. Results of the 
two analysts were found to be in congruence. 4) Homogene-
ity of codes within each theme and heterogeneity of codes 
across the themes were reviewed by other members of the 
research team to ascertain absence of overlapping categories. 
Themes not supported by adequate data were collapsed into 
other relevant themes or discarded. 5) The themes were 
refined according to the features exhibited by the data. 6) The 
report was written, and selected quotes of participants were 
excerpted to support the themes.
Results
Data saturation, as determined by no appearance of new 
themes, occurred after 18 patients were interviewed. Ten of 
the participants were recruited out of 132 eligible patients from 
AH, and eight were recruited out of 59 eligible patients from 
UMMC. Of the 21 CML patients invited, three refused to par-
ticipate due to a preference not to recall past treatment experi-
ences (n=1), lack of time (n=1), or mild hearing impairment 
(n=1). Eight interviews were conducted in English, eight in 
Malay, and two in Mandarin. The median duration of the 
interviews was 41 minutes (range: 20–64 minutes).
The age of recruited participants was between 26 and 
67 years, with nine aged 50 years, and nine aged 50 
years. Participants mostly attained secondary education 
(n=9) or tertiary education (n=7), while two received primary 
education. The majority of CML patients were diagnosed 
in the chronic phase (n=15) with duration ranging from 
3 months to 16 years. Most participants were on imatinib 
(n=13) as first-line therapy, while others had been started on 
imatinib but had switched over to nilotinib (n=5). Among 
the 15 participants who had been treated with TKIs for more 
than a year, disease status was as follows at the time of the 
interview: one patient had undetectable disease, seven had 
a major molecular response, six were not at the optimal 
benchmark of molecular disease control,6 and one was in 
blast crisis (Table 2).
Four themes of medication-related issues affecting 
adherence to TKIs were generated from the perspectives and 
experiences of the participants as shown in Figure 1.
concerns about adverse reactions 
to TKis
Despite participants’ awareness that TKI can save their lives, 
many were psychologically reluctant to take the medicine 
because of negative emotions toward adverse effects they 
experienced or potential harm that they had read or heard 
about. Some participants delayed their TKI doses as they 
were worried that vomiting or discomfort may disrupt their 
daily activities. Participants also complained that supportive 
therapy such as antiemetic medications given by their 
treating physicians was not effective. Some even skipped 
their TKIs to prevent wastage of the medication from poorly 
controlled vomiting.
Table 1 interview schedule
could you tell me about your experience of taking the medicine for 
chronic myeloid leukemia?
What problems or difficulties have you had while taking this medicine?
How do you cope with the problems or difficulties while taking this 
medicine?
What are your worries about taking this medicine?
can you describe to me in detail how you take this medicine?
What is your opinion about taking this medicine?
What do you think needs to be improved?
is there anything else you would like to discuss about the problems or 
difficulties while taking this medicine?
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There were times that I was sick, even with the smell of 
medication, I felt nausea. I know the medication is expen-
sive, (it would be) a waste if (I) were to take and vomit back 
out. I did not take. That’s the root cause that I progressed 
into stage 3. Unable to feed in the medication. [P16]
It will make you vomit, even if you take the medication 
that supposed to make you less nausea, but no [giggles] 
It doesn’t really help. I think the best option will be if they 
can reduce the side effect. Because that’s the reason why 
people stop taking medicine. If we take medicine every time 
then you go vomit, that’s a bit hard. [P17]
Participants who had experienced severe skin reactions 
expressed great concerns over their safety when rechallenged 
with the TKI after a gap. Furthermore, when adverse events 
Table 2 characteristics of participants
ID Gender Age, 
years
Ethnicity Education Marital 
status
Employment Duration 
of chronic 
myeloid 
leukemia
Disease 
phase at 
diagnosis
Tyrosine 
kinase 
inhibitor
Number of 
concomitant 
medications
Bcr-Abla
P1 Male 39 indian secondary single Unemployed 9 years chronic imatinib 2 Below the limit of 
detection
P2 Male 37 chinese secondary Married employed 6 years chronic imatinib 0 0.3011%
P3 Female 64 Malay secondary Married retired 4 years chronic imatinib 0 0.0114%
P4 Male 54 Malay secondary Married retired 6 years chronic nilotinib 0 46.0145%
P5 Female 62 Malay secondary Married homemaker 12 years chronic nilotinib 3 4.5100%
P6 Female 66 Malay secondary Divorced retired 3 months Accelerated nilotinib 6 not available
P7 Male 43 Malay Tertiary Married employed 5 years chronic imatinib 0 0.0501%
P8 Female 67 chinese secondary Married retired 4 years chronic imatinib 1 0.0362%
P9 Male 30 Malay secondary Married employed 14 years chronic nilotinib 0 3.5377%
P10 Female 55 chinese secondary Married homemaker 2 years chronic imatinib 0 0.0201%
P11 Male 32 Malay Tertiary single employed 8 months chronic imatinib 4 not available
P12 Male 26 chinese Tertiary single employed 3 years chronic imatinib 0 not available (white 
blood cell count in 
109 per liter =52.96)
P13 Female 52 indian Primary Married homemaker 11 years chronic imatinib 1 0.0551%
P14 Male 34 indian Tertiary single employed 16 years chronic imatinib 0 0.0420%
P15 Female 38 Malay Tertiary Married employed 8 years Accelerated imatinib 0 0.0485%
P16 Female 61 Malay Primary Married homemaker 6 years Accelerated imatinib 5 not monitored 
(progress to acute 
myeloid leukemia)
P17 Female 27 Malay Tertiary single employed 4 years chronic imatinib 0 0.1720%
P18 Male 35 Malay Tertiary Married employed 3 years chronic nilotinib 0 not monitored
Note: adenotes latest reading at the time of interview in international scale.
Figure 1 Themes of medication-related issues affecting chronic myeloid leukemia patients’ adherence to tyrosine kinase inhibitors (TKis).
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such as renal failure, chronic back pain, or dysphagia from 
chronic esophagitis were reported, participants felt certain 
that the TKI was the cause and expressed ambivalence toward 
their ongoing therapy. Uncertainties related to the risk of 
drug resistance on continuous TKI therapy also worried the 
participants. Driven by the fear of potential harm from long-
term TKIs, some participants modified their TKI regimens 
from routine to intermittent use without disclosing this to 
their health care providers.
The problem is we do not know when the condition will 
be stable because some of the drugs will cause resistance 
of your genes, so your genes at the end will eventually go 
mutated. And that’s very worrying for me, I don’t know 
when is the last day I need to take medications. [P12]
I was afraid that this medicine might cause side effects, 
so I dare not take it. In a week, I will take 5 days, skip 
2 days. [P10]
Personal beliefs regarding the use of TKis
Participants’ perceptions of the need to escalate their TKI dose 
when advised by their clinician, or to continue with therapy 
after their condition stabilized, varied and were influenced 
by their sociocultural background and disease knowledge. 
For example, to avoid the stigma of disclosing their disease 
through the visibility of taking TKIs in a workplace, some 
participants preferred less frequent dosing. Participants were 
also misled by family members and friends into believing 
the curative claims of traditional medicines, and some even 
stopped their CML treatment to try traditional medicines 
without consulting their health care providers.
The Malays they do believe that traditional medication 
could help, you know. After I was diagnosed for 2 months, 
a friend of mine told me that I could take lingzhi from China. 
Because from the readings that I made, it can cure even. 
Of course I would want to be cured right, so I told myself 
maybe this is the right thing. They said but I cannot take it 
together with the medication from the doctor, so I stopped 
the medication for a month. Then that’s it, my condition 
was worsening. [P15]
Many participants had misconceptions that the need to 
take their TKI could be judged according to their disease 
signs and symptoms. Consequently, participants experi-
mented with stopping the TKI on their own after regaining 
their premorbid health status. In particular, one participant 
repeatedly discontinued his TKI even after relapse of his 
CML into blast crisis as he did not understand the need to con-
tinue therapy when test results were normal. Paradoxically, 
participants who were informed that they were not respond-
ing well to their TKI still claimed it was effective after they 
perceived some form of improvement in their symptoms. 
This phenomenon could be due to fear of further therapy, 
especially bone marrow transplantation.
They said your CML has really relapsed in third stage. I keep 
pleading, no, pleading, pleading to the doctor. Because 
I don’t know I’m really into a very serious stage already. 
Then I followed the advice from the doctors, then I took the 
medications again. Yes, now I stopped for 2 months already. 
But everything seems well. They still mention need to be sta-
bilized, but they say so far your number (blood cell counts) 
seem alright, around that figure [snapped fingers]. [P12]
I’m not sure because by taking this medication, I feel 
well. Compared to the times I was sick, my weakness has 
reduced. Stomach has already healed, back to normal. 
I think this medication gives good effects, but doctor said 
it does not reflect well on my body. [P18]
Mismanagement of TKis in daily lives
Participants felt that the dosing requirements of TKIs were 
too complicated to follow. Some participants who reported 
nausea on imatinib had not adhered to the requirement to 
take doses after meals. Instead, they delayed the medication 
timing on the basis of subjective feelings of hunger or to 
protect concomitant medications. Other participants revealed 
not taking their nilotinib on an empty stomach because the 
time needed for fasting interfered with their busy schedule, 
thus putting them at risk of adverse drug–food interactions. 
Some Muslim patients who adjusted their TKI schedules 
to fulfill religious commitments during the fasting month 
of Ramadan also reported toxicities due to inappropriate 
dosing intervals.
Actually nobody advise, doctor said it’s after food, but they 
didn’t specifically say directly after food. Initially I thought 
if I take everything together, then when I vomit, everything 
will come out, no point also I’m taking the medicine. So I 
just take my diabetes and blood pressure (pills) first, then 
after 1 hour only I take my Gleevac. So it [chuckles] it 
doesn’t work like that, I mean it’s getting worse. [P11]
During the fasting month, I took breakfast at 5 o’clock 
and [I] took [nilotinib]. On the night before, I took it at 
11 o’clock, so 6 hours (dosing interval). Its overdose, 
I can feel my body aching, like what I have experienced 
initially. [P09]
Participants also expressed difficulties in managing 
their TKI regimens, leading to unintentional dose skipping. 
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This was often attributed to human nature such as a sudden 
slip of the mind when distracted, or tiredness. When partici-
pants were unsure whether they had taken their TKI, most 
of them chose not to take it due to concern about overdose, 
although one participant mentioned the possibility of doubling 
the dose due to a lack of means to monitor adherence.
It’s just like a night routine for me. But you know sometimes 
even though it’s a routine, but we tend to forget. Sometimes, 
I didn’t take the medicine for you know, a few days straight. 
And when I came to the hospital, the blood test result was 
not good. [P15]
It’s the feeling that I seem to have taken, but it seems 
I have not, so at the end I took, maybe sometimes I have 
doubled (dose). I would just take whichever tablet that I 
have removed from the blister pack. Since many rows were 
opened, I have no clue whether I have taken or not. [P10]
Financial burden in accessing treatment
Obstacles in accessing CML treatment due to public health 
policies were other issues voiced by participants. Two par-
ticipants, including a foreigner in Malaysia and a citizen 
who left the country to study abroad, could not be initiated 
on TKIs until 2 to 3 years into the diagnosis due to payment 
policy constraints in relation to the high price of TKIs. In 
addition, those who were not treated in a Ministry of Health 
facility struggled to cope with the out-of-pocket expenses 
for polymerase chain reaction tests for monitoring treatment 
responses to TKIs.
I was actually from Country X, before I got identifica-
tion card, I was not entitled to Gleevac and Tasigna. So 
I received Gleevac and Tasigna a bit later. Hydroxyurea 
cannot change that marker, Gleevac can, but maybe (I was 
without Gleevac for) too long, so the drug was less [effec-
tive]. [P04]
Because the medicine I cannot stop, that’s my wor-
ries [chuckles] So how long … right? Now the cost of the 
hospital has increased. Before [this] my blood test BCR-
ABL is free, now I need to pay hundred over. For private 
we struggle. [P07]
For participants from low-income families, transportation 
costs associated with travelling long distance to attend treat-
ment follow-ups still posed a huge financial burden despite 
gaining access to TKIs at no cost. Work commitments also 
caused some participants to miss scheduled medical assess-
ment, especially frequent monitoring for unstable responses, 
as well as medication refill visits, thereby resulting in inter-
ruptions of their TKI therapy.
Most of the people in village who always fall sick could not 
go to the hospital, this is the problem. Finance. Now, finance 
is really needed. We want to go to the hospital, there’s no 
vehicle, vehicle got to pay, that is difficult. Go once can, 
second time can, third time cannot go already because of 
insufficient finance. [P16]
Discussion
This study found that CML patients from two health care 
facilities in Malaysia encountered a range of medication- 
related issues. These led to a complex pattern of nonadherence 
behaviors to TKIs such as dose skipping, self-modification of 
dosing regimen and schedule, self-discontinuation of therapy, 
and even overadherence characterized by unintentional dou-
bling of doses or refusal to be taken off ineffective TKIs. The 
four themes of medication-related issues that emerged from 
this study ranged from patients’ concerns and misconceptions 
regarding effects of TKIs through to practical obstacles in 
handling medication routines and treatment-related out-of-
pocket expenses.
It has been reported that 23% of Malaysian CML patients 
taking imatinib experienced gastrointestinal side effects.19 
This accords with previous reports identifying nausea as a 
major cause of nonadherence to imatinib.16,26 Concern raised 
by patients over the long-term safety of TKIs is also in keep-
ing with a German survey that found that the fear of harmful 
effects from TKIs ranked even higher than the fear of CML 
progression.27 While Chen et al17 reported that knowledge of 
potential for drug resistance served as a positive motivation 
for sustaining imatinib adherence among Taiwanese CML 
patients, the present study showed contradictory findings.
A previous survey found that 24% of patients with 
hematological cancers in Malaysia use complementary and 
alternative medicine to cure their cancers.28 Generally, Asians 
believe that traditional medicines are from natural sources 
and are therefore safe. It is possible that our finding that 
some Malaysian CML patients prefer alternative medicine 
over TKIs could lead to poorer outcomes if they miss being 
treated in the chronic phase and instead take their TKI 
treatment only during the advanced phase, when disease 
burden is higher.29
This study indicated that some Malaysian CML patients 
have a misconception that TKI therapy needs to be continued 
only while they are symptomatic. This suggests an incomplete 
understanding of the disease and also implies that patients 
tend to focus on immediate treatment experiences rather 
than potential repercussions since disease progression or 
treatment failure may not be immediately evident following 
nonadherence. Similar findings have been reported in other 
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chronic disease states where patients appear less likely 
to adhere to their medication regimen in the absence of 
symptoms.30 Scheduling regular patient contacts in between 
clinic visits with a member of the multidisciplinary health 
care team such as a pharmacist or a nurse so that potential 
adherence issues could be recognized, discussed, and 
addressed in a timely manner can be an effective method of 
improving adherence.12,31
The results of the present study echo those of a survey 
in Europe that found that 30% of CML patients reported 
difficulties in coping with the dietary restrictions and dosing 
schedule of their TKIs, which in turn correlated negatively 
with treatment adherence.32 Strict adherence to the fasting 
requirement of nilotinib is necessary due to potential car-
diotoxicity, including sudden cardiac death.33 Therefore, it 
is essential that patients are fully guided on how to integrate 
TKIs into their personal schedules, taking into account any 
concomitant medications, and religious or other routines.
This study also highlighted a lack of means for patients 
to ascertain their own medication adherence. Developing 
appropriate patient reminders such as calendar charts or 
electronic reminders34 may reduce forgetfulness and help 
patients stay organized with their prescribed TKI regimen, 
thereby avoiding both untoward consequences of treatment 
failure and accidental overdose.
In Malaysia, health care facilities that provide cancer 
services are located mostly in the major cities, and some are 
partially subsidized by the government. The current study 
demonstrates that this limits the accessibility and afford-
ability of treatment, both of which are significant barriers to 
TKI adherence. This is consistent with a Japanese survey that 
found that CML patients with higher out-of-pocket medical 
expenses were more likely to discontinue or temporarily stop 
refilling their imatinib prescriptions.35
This study is the first to focus on medication-related 
issues among CML patients treated on TKIs in Malaysia 
using qualitative methodology. The findings of this study 
offer insights into the issues encountered by CML patients 
in accessing treatment and in self-administration, self- 
management, and self-monitoring of TKIs that have impor-
tant implications for the clinical effectiveness of this therapy. 
Consequently, measures addressing these issues need to be 
planned and implemented to support CML patients’ long-
term adherence to TKIs.
One of the main limitations of this study lies with 
the translation of Malay and Mandarin transcripts, as the 
intended meaning conveyed by the patients may not be pre-
cisely relayed in English. In addition, we did not have the 
capacity to utilize Tamil, which is another major language 
in our region of Malaysia, so the views and experiences of 
primarily Tamil-speaking patients have not been studied. We 
also acknowledge the limited recruitment of patients to only 
two public hospitals in Malaysia. These limitations make it 
difficult to generalize the results to the experiences of CML 
patients receiving TKI therapy in private health care facilities, 
or from other regions in Malaysia, and constitute potential 
avenues for future research.
Conclusion
Malaysian CML patients encountered a range of medication-
related issues leading to a complex pattern of nonadherence 
to TKIs. While drug resistance due to mutation is a non-
modifiable factor limiting the optimal clinical benefits of 
TKIs, nonadherence is a major modifiable factor. Improving 
communication to ensure patients fully understand the 
significance of the treatment responses for their long-term 
outcomes, eliciting and addressing patients’ concerns 
about treatment tolerability and safety, and empowering 
patients with the skills to self-manage their medications 
might promote better adherence to TKIs and improve 
treatment outcome.
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